Department of Tumor Biological treatment, the Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China.
J Transl Med. 2013 Mar 28;11:83. doi: 10.1186/1479-5876-11-83.
The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer patients. Such antitumor cellular immune responses can be greatly enhanced by adoptive transfer of activated type 1 lymphocytes. Recently, adoptive cell therapy based on infusion of ex vivo expanded TILs has achieved substantial clinical success. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8 T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Preclinical studies of CIK cells in murine tumor models demonstrate significant antitumor effects against a number of hematopoietic and solid tumors. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with comparable malignancies. Enhancing the potency and specificity of CIK therapy via immunological and genetic engineering approaches and identifying robust biomarkers of response will significantly improve this therapy.
免疫细胞数量，尤其是树突状细胞和细胞毒性肿瘤浸润淋巴细胞（TIL），特别是 Th1 细胞、CD8 T 细胞和 NK 细胞，与癌症患者的生存率增加有关。通过过继转移激活的 1 型淋巴细胞，可以极大地增强这种抗肿瘤细胞免疫反应。最近，基于输注体外扩增的 TIL 的过继细胞疗法取得了显著的临床成功。细胞因子诱导的杀伤（CIK）细胞是一群异质性的效应 CD8 T 细胞，具有不同的 TCR 特异性，对肿瘤细胞具有非 MHC 限制的细胞溶解活性。在小鼠肿瘤模型中的 CIK 细胞的临床前研究表明，其对多种血液系统肿瘤和实体瘤具有显著的抗肿瘤作用。临床研究证实了 CIK 细胞疗法对具有可比性的恶性肿瘤患者的益处和安全性。通过免疫和遗传工程方法增强 CIK 治疗的效力和特异性，并确定强大的反应生物标志物，将显著改善这种治疗。
